Abstract | BACKGROUND: PATIENTS AND METHODS: Patients were treated with radiotherapy (25 fractions at 2.0 Gy per fraction) five times per week for 5 weeks. Raltitrexed was administered on days 1 and 22 at 2.0, 2.6 and 3.0 mg/m(2). RESULTS: A total of 20 patients were entered into the study. Dose-limiting toxicities were recorded in three of 20 patients following the first dose of raltitrexed; one patient at 2.6 mg/m(2) (grade 3 diarrhoea, grade 3 neutropenia and grade 2 pyrexia) and two patients at 3.0 mg/m(2) (one grade 3 neutropenia and one grade 4 diarrhoea). The most common non-haematological and haematological treatment-related adverse events were diarrhoea (11 of 20, two grade 3, one grade 4) and leukopenia (eight of 20, one grade 3, one grade 4), respectively. CONCLUSIONS:
|
Authors | R D James, N Botwood, C C Vernon, P Price |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 14
Issue 4
Pg. 570-3
(Apr 2003)
ISSN: 0923-7534 [Print] England |
PMID | 12649103
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Quinazolines
- Thiophenes
- raltitrexed
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, pharmacology)
- Combined Modality Therapy
- Diarrhea
(chemically induced)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, pathology, radiotherapy)
- Neutropenia
(chemically induced)
- Quinazolines
(administration & dosage, pharmacology)
- Rectal Neoplasms
(drug therapy, pathology, radiotherapy)
- Thiophenes
(administration & dosage, pharmacology)
|